Recent progress in liver X receptor-selective modulators

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 4, 2010, Pages 403-413

  Ratni, Hassen ^a   Wright, Matthew B ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

ABCA1; atherosclerosis; dyslipidemia; HDL; inflammation; LXR; Lxr ; Lxr ; modulator; nuclear hormone receptor; SREBP1C

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; ABC TRANSPORTER G1; CS 8080; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MEH 184; MEH 185; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT; QUINOLINE DERIVATIVE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; T 1317; UNCLASSIFIED DRUG; WAY 214950; WAY 252623; WAY 254011; XL 652; 2-(2-CHLORO-4-FLUOROBENZYL)-3-(4-FLUOROPHENYL)-7-(TRIFLUOROMETHYL)-2H-INDAZOLE; BENZOIC ACID DERIVATIVE; BENZYLAMINE DERIVATIVE; FLUORINATED HYDROCARBON; INDAZOLE DERIVATIVE; LIGAND; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; PROTEIN BINDING; SULFONAMIDE; TO-901317;

CHEMISTRY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; LIGAND BINDING; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; X RAY ANALYSIS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; LIVER; METABOLISM; PHYSIOLOGY;

ANIMALS; BENZOATES; BENZYLAMINES; HUMANS; HYDROCARBONS, FLUORINATED; INDAZOLES; LIGANDS; LIVER; ORPHAN NUCLEAR RECEPTORS; PROTEIN BINDING; SULFONAMIDES;

EID: 77954643389     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Peet DJ, Janowski BA, Mangelsdorf DJ: The LXRs: A new class of oxysterol receptors. Curr Opin Genet Dev (1998)8(5):571-575.
2. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS: The liver X receptor ligand T0901317 decreases amyloid β production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2005)280(6):4079-4088.
3. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bjorkhem I, Pettersson S, Gustafsson JA: Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J Clin Invest (2001)107(5):565-573.
4. Quinet EM, Savio DA, Halpern AR, Chen L, Schuster GU, Gustafsson J-A, Basso MD, Nambi P: Liver X receptor (LXR)-β regulation in LXRα-deficient mice: Implications for therapeutic targeting. Mol Pharmacol (2006)70(4):1340-1349.
5. Beltowski J: Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc Ther (2008)26(4):297-316.
6. Bennett DJ, Carswell EL, Cooke AJ, Edwards AS, Nimz O: Design, structure activity relationships and X-ray co-crystallography of non-steroidal LXR agonists. Curr Med Chem (2008)15(2):195-209.
7. Bennett J, Cooke A, McKinnon HJ, Nimz O: LXR agonists for the treatment of atherosclerosis: Recent highlights. Annu Rep Med Chem (2008) 43: 103-117.
8. Goodwin BJ, Zuercher WJ, Collins JL: Recent advances in liver X receptor biology and chemistry. Curr Top Med Chem (2008)8(9):781-791. • A good review that summarizes the potential therapeutic utility of LXR modulators.
9. Hu B, Collini M, Unwalla R, Miller C, Singhaus R, Quinet E, Savio D, Halpern A, Basso M, Keith J, Clerin V et al: Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis. J Med Chem (2006)49(21):6151-6154.
10. Farnegardh M, Bonn T, Sun S, Ljunggren J, Ahola H, Wilhelmsson A, Gustafsson JA, Carlquist M: The three-dimensional structure of the liver X receptor β reveals a flexible ligandbinding pocket that can accommodate fundamentally different ligands. J Biol Chem (2003)278(40):38821-38828.
11. Hu B, Quinet E, Unwalla R, Collini M, Jetter J, Dooley R, Andraka D, Nogle L, Savio D, Halpern A, Goos-Nilsson A et al: Carboxylic acid based quinolines as liver X receptor modulators that have LXRβ receptor binding selectivity. Bioorg Med Chem Lett (2008)18(1):54-59.
12. Wyeth [Pfizer Inc] (Wrobel JE, Hu B, Collini MD, Jetter JW, Bernotas RC, Kaufman DH, Singhaus RR Jr, Ullrich JW, Morris RL, Unwalla RJ): Quinoline acids. US-20090069373 (2009).
13. Bernotas RC, Singhaus RR, Kaufman DH, Ullrich J, Fletcher H 3rd, Quinet E, Nambi P, Unwalla R, Wilhelmsson A, Goos-Nilsson A, Farnegardh M et al: Biarylether amide quinolines as liver X receptor agonists. Bioorg Med Chem (2009)17(4):1663-1670.
14. Bernotas RC, Kaufman DH, Singhaus RR, Ullrich J, Unwalla R, Quinet E, Nambi P, Wilhelmsson A, Goos-Nilsson A, Wrobel J: 4-(3-Aryloxyaryl) quinoline alcohols are liver X receptor agonists. Bioorg Med Chem (2009)17(23):8086-8092.
15. Bernotas RC, Singhaus RR, Kaufman DH, Travins JM, Ullrich JW, Unwalla R, Quinet E, Evans M, Nambi P, Olland A, Kauppi B et al: 4-(3-Aryloxyaryl) quinoline sulfones are potent liver X receptor agonists. Bioorg Med Chem Lett (2010)20(1):209-212.
16. Wyeth [Pfizer Inc] (Bernotas RC, Singhaus RR Jr, Ullrich J W, Kaufman DH, Morris RL, Wrobel JE, Hu B, Jetter JW, Collini MD, Travins JM, Magolda RL): Quinoline compounds. WO-2008049047 (2008).
17. Wyeth [Pfizer Inc] (Hu B, Wrobel JE, Collini MD, Unwalla RJ): Cinnoline compounds and their use as liver X receptor modulators. WO-2006094034 (2006).
18. Hu B, Unwalla R, Collini M, Quinet E, Feingold I, Goos-Nilsson A, Wihelmsson A, Nambi P, Wrobel J: Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRβ. Bioorg Med Chem (2009)17(10):3519-3527.
19. Wyeth [Pfizer Inc] (Bernotas RC, Ullrich JW, Travins JM, Wrobel JE, Unwalla RJ): Quinazoline compounds. WO-2009020683 (2009).
20. Wrobel J, Steffan R, Bowen SM, Magolda R, Matelan E, Unwalla R, Basso M, Clerin V, Gardell SJ, Nambi P, Quinet E et al: Indazolebased liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J Med Chem (2008)51(22):7161-7168. •• Describes the discovery and preclinical profile of WAY-252623.
21. Quinet EM, Basso MD, Halpern AR, Yates DW, Steffan RJ, Clerin V, Resmini C, Keith JC, Berrodin TJ, Feingold I, Zhong W et al: LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res (2009)50(12):2358-2370. •• Reports preclinical data for WAY-252623, including species differences in activity.
22. Wyeth [Pfizer Inc] (Bernotas RC, Travins JM, Wrobel JE, Kaufman DH): Benzimidazole compounds. WO-2009086138 (2009).
23. Travins JM, Bernotas RC, Kaufman DH, Quinet E, Nambi P, Feingold I, Huselton C, Wilhelmsson A, Goos-Nilsson A, Wrobel J: 1-(3-Aryloxyaryl) benzimidazole sulfones are liver X receptor agonists. Bioorg Med Chem Lett (2010)20(2):526-530.
24. Singhaus RR, Bernotas RC, Steffan R, Matelan E, Quinet E, Nambi P, Feingold I, Huselton C, Wilhelmsson A, Goos-Nilsson A, Wrobel J: 3-(3-Aryloxyaryl) imidazo[1, 2-a]pyridine sulfones as liver X receptor agonists. Bioorg Med Chem Lett (2010)20(2):521-525.
25. Wyeth [Pfizer Inc] (Singhaus RR, Bernotas RC, Wrobel JE, Steffan RJ, Matelan EM): Imidazo [1, 2-a] pyridine compounds. WO-2009086123 (2009).
26. Wyeth [Pfizer Inc] (Singhaus RR): Imidazo [1, 2-b] pyridazine compounds as modulators of liver X receptors. WO-2009086130 (2009).
27. Wyeth [Pfizer Inc] (Singhaus RR): Pyrazolo [1, 5-a] pyrimidine compounds. WO-2009086129 (2009).
28. Hu B, Bernotas R, Unwalla R, Collini M, Quinet E, Feingold I, Goos-Nilsson A, Wilhelmsson A, Nambi P, Evans M, Wrobel J: Quinoline-3- carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRβ and low blood-brain penetration. Bioorg Med Chem Lett (2010)20(2):689-693.
29. Kowa Co Ltd (Okuda A, Matsuda T, Miura T, Yamazaki K, Yamaguchi Y, Koura M, Kurobuchi S, Watanabe Y, Shibuya K): 1, 3-Dihydroisobenzofuran derivatives. US-20090248587 (2009).
30. Kowa Co Ltd (Okuda A, Matsuda T, Miura T, Ozawa H, Tosaka A, Yamazaki K, Yamaguchi Y, Kurobuchi S, Watanabe Y, Shibuya K): 2-Oxochromene derivative. WO-2009107387 (2009).
31. Kowa Co Ltd (Koura M, Okuda A, Matsuda T, Yamaguchi Y, Sumida H, Kurobuchi S, Watanabe Y, Enomoto T, Shibuya K): Quinoline compound. WO-2009133692 (2009).
32. Kowa Co Ltd (Matsuda T, Okuda A, Koura M, Yamaguchi Y, Kurobuchi S, Watanabe Y, Shibuya K): Substituted carbinol compound. WO-2008065754 (2008).
33. Kowa Co Ltd (Yamaguchi Y, Koura M, Kurobuchi S, Matsuda T, Okuda A, Sumida H, Watanabe Y, Enomoto T, Shibuya K): Substituted carbinol compound having cyclic linker. WO-2009144961 (2009).
34. Kowa Co Ltd (Koura M, Okuda A, Matsuda T, Yamaguchi Y, Sumida H, Kurobuchi S, Watanabe Y, Enomoto T, Shibuya K): A novel substituted carbinol compound. JP-2009286788 (2009).
35. Kowa Co Ltd (Matsuda T, Nakajima H, Tosaka A, Watanabe Y): LXR agonist. JP-2008179562 (2008).
36. Marino JP Jr, Kallander LS, Ma C, Oh HJ, Lee D, Gaitanopoulos DE, Krawiec JA, Parks DJ, Webb CL, Ziegler K, Jaye M et al: The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages. Bioorg Med Chem Lett (2009)19(19):5617-5621.
37. Washburn DG, Hoang TH, Campobasso N, Smallwood A, Parks DJ, Webb CL, Frank KA, Nord M, Duraiswami C, Evans C, Jaye M et al: Synthesis and SAR of potent LXR agonists containing an indole pharmacophore. Bioorg Med Chem Lett (2009)19(4):1097-1100.
38. City of Hope (Forman B): Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof. US-20090030082 (2009). • Interesting patent demonstrating that subtle chemical modifications may alter the LXR-subtype selectivity profile of a series of compounds.
39. Ratni H, Blum-Kaelin D, Dehmlow H, Hartman P, Jablonski P, Masciadri R, Maugeais C, Patiny-Adam A, Panday N, Wright M: Discovery of tetrahydro- cyclopenta[b]indole as selective LXRs modulator. Bioorg Med Chem Lett (2009)19(6):1654-1657.
40. F Hoffmann-La Roche Ltd [Roche Holding AG] (Dehmlow H, Obst Sander U, Schulz-Gasch T, Wright M): Imidazolidine derivatives. WO-2009150109 (2009).
41. F Hoffmann-La Roche Ltd [Roche Holding AG] (Dehmlow H, Obst Sander U, Schulz-Gasch T, Wright M): Biaryl sulfonamide derivatives. WO-2009040289 (2009).
42. F Hoffmann-La Roche Ltd [Roche Holding AG] (Dehmlow H, Kuhn B, Obst Sander U, Roever S, Schulz-Gasch T, Wright M, Wyler R): Novel piperazine amide derivatives. WO-2009021868 (2009).
43. Hoffmann-La Roche Inc (Dehmlow H, Kuhn B, Sander UO, Roever S, Schulz-Gasch T, Wright M): Imidazolidinone derivatives. US-20080242677 (2008).
44. Swahn BM, Macsari I, Viklund J, Ohberg L, Sjodin J, Neelissen J, Lindquist J: Liver X receptor agonists with selectivity for LXRβ; N-aryl-3, 3, 3-trifluoro-2-hydroxy-2-methylpropionamides. Bioorg Med Chem Lett (2009)19(7):2009-2012.
45. Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S: Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther (2008)327(2):332-342. •• Provides a particularly interesting discussion of tissue-selective agonists and questions the theory that simple isoform (LXRβ) selectivity is sufficient to reduce side-effects.
46. Cheng JF, Zapf J, Takedomi K, Fukushima C, Ogiku T, Zhang SH, Yang G, Sakurai N, Barbosa M, Jack R, Xu K: Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators. J Med Chem (2008)51(7):2057-2061. • Describes the use of an innovative cellular screen, employing high-throughput gene expression profiling of ten LXR target genes.
47. Organon BioSciences [Merck & Co Inc] (Cooke AJ, Edwards AS, Andrews FE, Bennett DJ, Nimz O, Carswell EL): N-(1, 1, 1, 3, 3, 3-Hexafluoro-2- hydroxypropan-2-yl) benzyl-N'-arylcarbonylpiperazine derivatives. WO-2009138438 (2009).
48. Organon BioSciences [Merck & Co Inc]/Pharmacopeia Inc [Ligand Pharmaceuticals Inc] (Ho K-K, Roughton AL, Neagu I, Chan J-H, Ansari N, Morris ML, Rong Y, Ohlmeyer M, Cooke AJ, Edwards AS, Bennett DJ): N-Benzyl, N'-arylcarbonylpiperazine derivatives as LXR modulators. WO-2009024550 (2009).
49. North China Pharmaceutical Group Corp New Drug Research and Development Co Ltd (Lu X, Zheng Z, Li Y, Ke A, Ma Y, Cui X, Shi Y, Zhu J, Ren X, Lin J, Ding Y et al): Novel LXR agonist as well as preparation method and application thereof. CN-101456863 (2009).
50. Kim KH, Choi SH, Lee TS, Oh WK, Kim DS, Kim JB: Selective LXRα inhibitory effects observed in plant extracts of MEH184 (Parthenocissua tricuspidata) and MEH185 (Euscaphis japonica). Biochem Biophys Res Commun (2006)349(2):513-518.
51. Janowski BA, Grogan MJ, Jones AS, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ: Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc Natl Acad Sci USA (1999)96(1):266-271.
52. Tamehiro N, Sato Y, Suzuki T, Hashimoto T, Asakawa Y, Yokoyama S, Kawanishi T, Ohno Y, Inoue K, Nagao T, Nishimaki-Mogami T: Riccardin C: A natural product that functions as a liver X receptor (LXR) α agonist and an LXRβ antagonist. FEBS Lett (2005)579(24):5299-5304.
53. Dodo K, Aoyama A, Noguchi-Yachide T, Makishima M, Miyachi H, Hashimoto Y: Co-existence of α-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem (2008)16(8):4272-4285.
54. Motoshima K, Noguchi-Yachide T, Sugita K, Hashimoto Y, Ishikawa M: Separation of α-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRα-selective antagonists. Bioorg Med Chem (2009)17(14):5001-5014.
55. Aoyama A, Aoyama H, Dodo K, Makishima M, Hashimoto Y, Miyachi H: LXR antagonists with a 5-substituted phenanthridin-6-one skeleton: Synthesis and LXR transrepression activities of conformationally restricted carba-T0901317 analogs. Heterocycles (2008)76(1):137-142.
56. Aoyama A, Aoyama H, Makishima M, Hashimoto Y, Miyachi H: Liver X receptor (LXR) modulators with dibenz[b, f]-[1, 4] oxazepin-11-one, (Z)-dibenz[b, f]azocin-6-one, and 11, 12-dihydrodibenz[b, f]azocin-6-one skeletons. Heterocycles (2009)78(9):2209-2216.
57. Tokyo University (Miyachi H, Hashimoto Y, Aoyama A): Tricyclic compound. WO-2009107389 (2009).
58. Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O, Meng X: Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol (2009)49(6):643-649. • Describes the pharmacokinetics, pharmacodynamics and safety profile of WAY-252623 in humans.
59. Exelixis: Third Annual R&D Day. (2007).
60. Exelixis 10-Q report: Faqs. Org (2009). www.faqs.org/sec-filings/091029/ EXELIXIS-INC-10-Q/